Champions Oncology, Inc. — Form 10-Q summary
Business context and period. The company develops Tumorgraft-based oncology services: Personalized Oncology Solutions (POS) for physicians and Translational Oncology Solutions (TOS) for pharmaceutical and biotechnology companies. This fiscal second-quarter report covers the three and six months ended October 31, 2011; comparisons are with the corresponding 2010 periods. Financial statement amounts below are in millions of dollars unless stated otherwise.
Financial performance
| Metric | Three months ended Oct. 31, 2011 | Six months ended Oct. 31, 2011 | Prior comparable period |
|---|---|---|---|
| Revenue | $1.741 million, up 87% | $3.372 million, up 33% | $0.933 million and $2.533 million, respectively |
| Operating loss | $(2.469) million | $(4.685) million | $(1.015) million and $(1.610) million |
| Net loss | $(2.349) million | $(4.387) million | $(0.054) million and $(0.645) million |
| Loss per share | $(0.05) | $(0.09) | $(0.00) and $(0.02), respectively |
| Operating cash used | $3.291 million for the six-month period | $1.186 million |
- Revenue mix: Q2 POS revenue was $0.590 million, up 100%; TOS was $1.151 million, up 78%. For six months, POS was $1.188 million, down 14%, while TOS was $2.184 million, up 92%.
- Gross margins: POS was 21.9% for Q2 and 20.5% for six months, versus 43.1% and 65.0%. TOS was 46.1% and 49.5%, versus 38.8% and 37.4%, respectively.
- Costs: Six-month sales and marketing expense rose to $1.262 million from $0.116 million; general and administrative expense rose to $3.130 million from $1.325 million. Research and development was $1.616 million versus $1.502 million.
- Cash and liquidity: At October 31, cash and cash equivalents were $7.119 million, restricted cash $0.150 million, working capital $5.4 million, and current liabilities $3.416 million. Cash and equivalents declined $3.338 million from April 30. Management said available cash was adequate to fund operations for at least 12 months.
- Debt and equity: The filing does not report conventional borrowings. Total liabilities were $4.100 million, including a $0.684 million warrant liability. The balance sheet classifies $8.159 million of common stock as redeemable temporary equity; stockholders’ equity was a deficit of $2.387 million. Cash from financing activities was $0.098 million, from warrant exercises.
Material changes and management commentary
- Q2 revenue growth was driven by both service lines; six-month TOS revenue approximately doubled. Management attributed TOS growth to increased sales efforts and investment in the Tumorbank.
- POS revenue for the half-year fell despite higher service volumes, as the company lowered prices to encourage volume. Management said the volume increase did not offset lower prices; POS margins also declined.
- Operating expenses and losses increased as the company expanded its sales force and marketing, grew personnel and incurred higher stock-based compensation. Six-month stock compensation was $1.868 million, versus $0.367 million.
- Prior-year other income included approximately $0.960 million in government grant income; current-period other income included a $0.288 million gain from the lower fair value of warrant liabilities. These items make year-over-year net-loss comparisons less indicative of underlying operations.
Outlook, risks and contingencies
- No specific revenue, earnings or margin guidance is provided. Management expects cash on hand to fund operations for at least 12 months, but cautions that future financing may not be available on acceptable terms and could dilute shareholders or impose restrictive terms.
- The April 2011 financing included investors’ rights to require cash redemption of certain shares at $0.75 per share upon a change of control or sale of substantially all assets, subject to termination conditions. Warrants have exercise-price reset provisions and are recorded as liabilities.
- Cephalon agreement: the company recognized $0.237 million of revenue through October 31 from a $1.4 million initiation payment initially deferred. Up to $27 million of milestone payments and potential royalties are contingent; none had been achieved or received at the filing date.
- An IRS examination of the company’s Qualifying Therapeutic Discovery Project grant applications was ongoing, including the fiscal 2011 return. The company said it did not expect a material effect and believed available net operating loss carryforwards would offset any adjustment. A $0.5 million grant-related amount remained unreceived; the filing lists a $0.517 million grant receivable.
- Potential registration-default penalties could total $41,000 per 30-day period. Management did not consider payment probable and recorded no accrual. The filing reports no litigation expected to have a material effect and no material changes to previously disclosed risk factors.
Most important facts for investors to verify
- Whether TOS growth and improved TOS margins can continue, and whether POS pricing changes can produce enough volume to restore margins.
- Cash burn, working-capital needs and management’s 12-month runway assessment, particularly if operating losses persist or financing is needed.
- Status and terms of the Cephalon studies, including revenue recognition, milestone conditions and the potential value and timing of payments.
- Outcome of the IRS examination and collection of the outstanding grant receivable.
- Potential effects of the redeemable-share put option, warrant reset provisions, warrant-liability valuation and any registration-rights penalties.
- Scale and persistence of stock-based compensation and its effect on reported losses and shareholder dilution.